| |
|
| 08:30 |
Registration and refreshments |
| |
|
| 09:00 |
Opening remarks from the Chair |
| |
|
| cGMP compliance |
| |
|
| 9:10 |
Understanding the specific requirements for cGMP compliance with respect to quality assurance, quality control and process optimisation processes |
| |
- Learning the latest updates on cGMP requirements to stay abreast with the evolving regulatory policy and development
- Identifying the existing gaps and discrepancies in Indian cGMP guidelines and fulfilling these to meet international standards
- Evaluating various quality control processes , quality assurance requirements and complete regulatory interface to comply with cGMP standards
- Understanding the manufacturing requirements with respect to plant area, equipment and processes to meet international quality and safety standards
- Highlighting the specific documentation requirements with respect to the updated GMP standards to ensure swift and smooth commercialisation of your product
- Case Study: Overcoming specific cGMP concerns raised in the emerging markets and effective strategies to deal with these
|
| |
Kamaal Anas, Senior Director Regulatory Affairs and Quality Assurance, IAVI USA |
| |
|
| Quality by Design |
| |
|
| 9:50 |
Understanding the role and importance of Quality by Design (QbD) in
manufacturing to ascertain its impact on vaccine development |
| |
- Determining the importance and scope of QbD in vaccines and biologicals to ensure high quality and ascertain cost benefits for manufacturers
- Evaluating the impact of implementing QbD on the quality and yield of the product to ensure a cost-effective manufacturing process
- Clarifying the complex ICH Q8/Q9/Q10 guidelines to ensure compliance with the global regulatory standards
- Determining the role of QbD with respect to plant layout to ascertain specific benefits and challenges faced in the development of vaccines
- Establishing best practice case studies on ‘Development of Design Space in QbD’
|
| |
Ganesh Kumraj, Industry Consultant |
| |
|
| 10:30 |
Morning refreshments and networking |
| |
|
| Upstream Processing and Scale up challenges |
| |
|
| 10:50 |
Determining and overcoming the specific challenges faced in upstream processing to ensure maximum yield through effective fermentation, cell structure and process development of vaccines |
| |
- Leveraging the latest developments in fermentation, aseptic connections, control of filters and duration of filters to achieve high quality with maximised yield
- Examining the process changes during scale-up and pro-rata scale-up to ascertain their impact on the overall yield of the product
- Determining the appropriate control parameters required for effective scale-up
- Navigating the complete regulatory landscape of the scale-up process – level 1,2 or 3 and validation of scale-up
- Highlighting success stories in the scada system for fermentation control, on-line pH and DO measurement
|
| |
Ravi Kanth Koneru, Bio Process and API Manufacturing Specialist (Vaccines)
The Biovac Institute South Africa |
| |
|
| Downstream Processing and Scale up challenges |
| |
|
| 11:30 |
Overcoming the specific issues and challenges faced in the downstream processing to ensure impurity-free and high quality vaccines |
| |
- Troubleshooting chromatography and filtration challenges to achieve the desired purity standards
- Establishing the need and importance of product concentration and identify various techniques for effective purification process
- Examining how process changes in scale-up and pro-rata scale-up impact the yield
- Determining the appropriate control parameters required for effective scale-up in the downstream processing
- Navigating the complete regulatory landscape of the scale up process – level 1,2 or 3 and validation of scale-up in downstream processing
- Devising effective strategies to overcome the hurdles faced in the downstream process to ensure purity and high yield
- Exploring best practice case studies on bio-controlled process versus aseptic process
|
| |
Ganesh Kumraj,
Industry Consultant |
| |
|
| Technology transfer |
| |
|
| 12:10 |
Troubleshooting technology transfer between R&D and manufacturing to ensure a swift, smooth and flawless transfer process |
| |
- Outlining the importance of effective technology transfer at different stages in the inlicensing procedures to avoid legal implications and ensure easy access to technical know-how
- Devising effective strategies to ensure smooth technology transfer with respect to processes, testing, raw materials and method of transfer
- Undertaking proactive measures to reduce the time lines and eliminate potential re-work
- Leveraging on the parent product data to ensure its effective usage in pre-clinical and
clinical data
- Overcoming specific challenges faced due to different locations, climatic conditions and other environmental problems to ensure smooth and flawless transfer procedures
- Emphasising on the need of appropriate co-ordination between R&D and manufacturing departments to ensure a smooth transfer process
- Analysing a case study on Japanese encephalitis
- Highlighting specific challanges in technology transfer of Hib (Haemophilus influenza type b) vaccine from research to production
|
| |
Goetz Reiner, Vice President Bulk Manufacturing, Biological E |
| |
|
| 12:50 |
Lunch and networking |
| |
|
| Virus Like Particle technology |
| |
|
| 13:50 |
Leveraging the latest advancements in Virus Like Particle (VLP) to ensure faster production, simple purification and high quality analysis |
| |
- Identifying how VLP vaccines are different to conventional vaccines
- Understanding and overcoming challenges in the clinical development of VLP vaccines to ensure high quality product
- Highlighting the specific benefits offered by VLP vaccines with respect to achieving full biocompatibility and biodegradability
- Determining the most effective techniques for simple purification and quality analysis
|
| |
|
| Disposable machinery/equipment |
| |
|
| 14:30 |
Determining the specific benefits offered by disposable machineries and equipment to ensure cost-effective, high quality vaccine production |
| |
- Comparing the benefits of one-time use machines with the regular ones to determine the differences with respect to cost, quality, speed and efficacy in vaccine production
- Determining innovative ways to control the manufacturing costs by continuous improvement in technologies with minimal changes in process scheme to ensure higher product quality
|
| |
|
| Cold chain management |
| |
|
| 15:10 |
Examining the latest innovations in dedicated cold chain and distribution system for vaccines to ensure flawless transit till it reaches the end user |
| |
- Understanding the cold chain management requirements for storage and distribution
- Assessing cold chain management needs of vaccines as against other biological products
- Overcoming the challenges of continuous monitoring of in-transit vaccine products
- Finding a cost-effective means of dealing with power cuts and other cold chain barriers
- Developing effective processes to ensure compliance with end-to-end cold chain culture
- Assessing state-of-the-art equipment for cold chain management of vaccines
- Determining the advances in validated packaging systems to identify the best ways to maintain the desired temperature during transit
- Leveraging on the optimisation of design, size and packaging for transportation of vaccines
- Tracking cold chain performance by innovative devices and technology throughout the shipment cycle
|
| |
R Ravichandran, Head International Business, Indian Immunologicals |
| |
|
| 15:50 |
Evaluating the most innovative methods for cold chain management to ensure stability of vaccines during the different stages of distribution |
| |
- Exploring the most effective cold chain options available for different stages of distribution including manufacturing site, CWH, CFAs, distributors and doctors
- Troubleshooting the maintenance of cold chain at various stages of distribution to determine the most effective and flawless maintenance system
- Analysing the most innovative solutions in cold chain management and understanding their cost and time benefits over traditional systems
|
| |
Rajkamal Singh Bhatia, Director Supply Chain and Business Support,
Sanofi Pasteur |
| |
|
| 16:30 |
Afternoon refreshments and networking |
| |
|
| Inventory management |
| |
|
| 16:50 |
Developing best practice strategies for effective inventory management to ensure optimum capacity of the manufacturing plant with minimum wastage |
| |
- Devising the most cost-effective strategies to ensure consistent raw material supply, the right equipments and the right resources
- Understanding innovative inventory management techniques to reduce cost, maintain quality and ensure timely delivery
- Identifying innovative techniques by predicting market requirements to ensure better inventory management
- Leveraging the latest developments and overcoming specific challenges faced in the 2D bar-coding system and RFID to track and trace the product till it safely reaches the end user
- Understanding with practical examples how to effectively link inventory management with market forecasting to ensure an appropriate demand-supply matrix
- Determining the most appropriate option for inventory management – comparing manufacturing site with CWH and CFAs
- Identifying the need for having a CWH, and it’s contribution towards efficient inventory management
- Establishing the most effective practices followed for maintaining inventory at primary and secondary levels for cold chain sensitive products
- Establishing the co-relation of product life cycle and inventory norms to ensure optimum quality and minimum wastage
|
| |
Rajkamal Singh Bhatia, Director Supply Chain and Business Support, Sanofi Pasteur |
| |
|
| Water purification system |
| |
|
| 17:30 |
Analysing the importance of a having an effective water purification system to determine its impact on the quality of vaccines |
| |
- Critically analysing the most appropriate alternative for your company - ‘Pure steam’ versus ‘Clean steam’
- Leveraging the latest developments in water purification systems for vaccines to ensure a clean and safe manufacturing process
|
| |
|
| Commercialisation and Brand building |
| |
|
| 18:10 |
Determining the opportunities and overcoming various challenges in the commercialisation of vaccines to ensure wider market coverage and maximum ROI |
| |
- Understanding the specific intricacies of catering to supranational organisations such as the UNICEF and PAHO
- Devising effective strategies to take vaccines to the non-donor international markets with special reference to Non-UN healthcare agency based public markets
- Devising effective strategies to take vaccines to the non-donor international markets with special reference to Non-UN healthcare agency based public markets
- Exploring the best strategies for brand building and direct intuitional supplies to private international markets to ensure swift and wider market reach
|
| |
Sangram Shirke, Head Marketing, Wockhardt |
| |
|
| 18:50 |
Close of Conference Day Two |
| |
|
| |
|
| |
|